TK216, a small-molecule ETS inhibitor initially designed to target an oncogenic fusion protein (EWS-FLI1) in Ewing sarcoma, is currently being studied in a phase 2 clinical trial (clinicaltrials.gov, NCT No. NCT05046314). The gene discussed is FLI1; the disease is Ewing sarcoma.